Pharma News

In a major advancement for HIV treatment, Gilead Sciences and Merck have announced positive topline results from two pivotal Phase 3 clinical trials evaluating an investigational once-weekly oral HIV therapy that combines islatravir and lenacapavir. The promising findings bring the healthcare industry one step closer to introducing what could become the world's first long-acting oral HIV treatment taken just once a week.

A groundbreaking European clinical trial has shown that using a common, harmless virus as a biomarker to guide immunosuppressive treatment after kidney transplantation is both safe and effective, paving the way for more personalized transplant care.

In a groundbreaking advancement for precision medicine, doctors in Israel have successfully administered the world's first gene replacement therapy directly into the brain of an infant suffering from a rare and devastating genetic epilepsy disorder. The experimental treatment aims to restore the function of the defective WWOX gene, offering new hope to children affected by this life-threatening condition.

Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.

Axsome Therapeutics has announced the resolution of all remaining patent litigation related to its wake-promoting medicine SUNOSI (solriamfetol), bringing an end to a series of legal disputes with generic drug manufacturers seeking U.S. market entry.

Researchers have identified four promising blood-based metabolites that may help distinguish individuals with latent tuberculosis infection (LTBI) from those without infection, according to a new study published in BIO Integration. The findings provide fresh insights into the metabolic changes associated with latent tuberculosis and could support the development of improved diagnostic approaches in the future.